Family · Pharmaceutical analytical standards
Fulvestrant
The first selective oestrogen receptor degrader (SERD), approved in the United States in 2002 and in Europe in 2004: it is given by intramuscular injection for hormone-sensitive breast cancer. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.
Did you know?It is built on the skeleton of oestradiol, the very hormone whose action it blocks: a long side chain at the 7-alpha position makes the receptor unstable, and the cell then destroys it.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
